CN114532468A - Efficacy-enhanced artemisia selengensis leaf uric acid-reducing beverage - Google Patents
Efficacy-enhanced artemisia selengensis leaf uric acid-reducing beverage Download PDFInfo
- Publication number
- CN114532468A CN114532468A CN202210210953.5A CN202210210953A CN114532468A CN 114532468 A CN114532468 A CN 114532468A CN 202210210953 A CN202210210953 A CN 202210210953A CN 114532468 A CN114532468 A CN 114532468A
- Authority
- CN
- China
- Prior art keywords
- artemisia selengensis
- percent
- uric acid
- extract
- selengensis leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001168877 Artemisia selengensis Species 0.000 title claims abstract description 56
- 235000015759 Artemisia selengensis Nutrition 0.000 title claims abstract description 55
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 235000013361 beverage Nutrition 0.000 title claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 68
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229940116269 uric acid Drugs 0.000 claims abstract description 37
- 230000001603 reducing effect Effects 0.000 claims abstract description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- 229920000858 Cyclodextrin Polymers 0.000 claims description 15
- 239000001116 FEMA 4028 Substances 0.000 claims description 15
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 15
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 15
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 15
- 229960004853 betadex Drugs 0.000 claims description 15
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 15
- 239000000811 xylitol Substances 0.000 claims description 15
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 15
- 229960002675 xylitol Drugs 0.000 claims description 15
- 235000010447 xylitol Nutrition 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 30
- 241000220317 Rosa Species 0.000 abstract description 15
- 210000003734 kidney Anatomy 0.000 abstract description 13
- 235000008113 selfheal Nutrition 0.000 abstract description 13
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 238000011084 recovery Methods 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000035622 drinking Effects 0.000 abstract 1
- 244000299788 selfheal Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 24
- 108010093894 Xanthine oxidase Proteins 0.000 description 17
- 102100033220 Xanthine oxidase Human genes 0.000 description 17
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 244000179560 Prunella vulgaris Species 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 201000001431 Hyperuricemia Diseases 0.000 description 10
- 230000001953 sensory effect Effects 0.000 description 10
- 241000213006 Angelica dahurica Species 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 241000125175 Angelica Species 0.000 description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 240000006122 Chenopodium album Species 0.000 description 3
- 235000009344 Chenopodium album Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 235000003826 Artemisia Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 244000030166 artemisia Species 0.000 description 2
- 235000009052 artemisia Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000005272 common selfheal Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
The invention discloses an efficacy-enhanced artemisia selengensis leaf uric acid reducing beverage, which takes artemisia selengensis leaf extracting solution as a main component, and is supplemented with selfheal extract, rose extract, spina date seed extract and radix angelicae extract, so that the prepared beverage has a more remarkable uric acid reducing effect, has a protection effect on kidney, is more beneficial to disease recovery and prevention, has good taste and is suitable for daily drinking.
Description
Technical Field
The invention relates to an efficacy-enhanced artemisia selengensis leaf uric acid-reducing beverage.
Background
With the development of economic society of China, the dietary demands and the quality of life of people are continuously improved, and meanwhile, the working pressure is gradually increased, and hyperuricemia becomes an invisible killer threatening the health of people. In recent years, the prevalence of hyperuricemia has increased year by year, and the average age of the affected population has exhibited a decreasing trend. The data show that nearly 10% of patients with hyperuricemia suffer from gout, and therefore, it is critical to prevent and treat gout to avoid uric acid accumulation.
Modern medicine considers that the kidney is the main place for generating human urine (uric acid), and hyperuricemia is caused by the increase of uric acid production in a human body and the reduction of uric acid secretion of the kidney, so that gout is directly induced. At present, medicines are generally used for reducing the concentration of uric acid in blood so as to prevent gout, such as allopurinol, febuxostat and the like, but the medicines have certain defects in treatment, have the effects of treating symptoms and root causes but not treating the root causes, have large side effects, even cause or aggravate kidney injury, and are not beneficial to long-term application in reducing uric acid or preventing uric acid increase. Therefore, the research and development of the uric acid-reducing health/functional food which is natural in source, safe and effective and can treat both symptoms and root causes has important social and economic significance.
Artemisia Selengensis Turcz (Artemisia Selengensis Turcz) which is also called Artemisia Selengensis and Artemisia betel, is perennial herb of Artemisia in Compositae, has a long history of eating, the main eating part of the Artemisia Selengensis is tender stem, and a large amount of Artemisia Selengensis leaves cannot be eaten due to bitter taste and excessive discard. Researches show that the artemisia selengensis leaves are rich in flavonoids, have the activities of regulating purine metabolism key enzymes and reducing the concentration of blood uric acid, have great potential for developing anti-gout products, but the efficacy of the existing artemisia selengensis leaf beverage is still required to be further improved.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention screens and obtains the artemisia selengensis leaf uric acid reducing beverage with enhanced efficacy by taking natural medicinal botanics as a basis and combining a modern pharmacological pharmacodynamics research method, the uric acid reducing efficacy of the artemisia selengensis leaf is further improved by adding four plant extracts of common selfheal fruit-spike, rose, spina date seed and dahurian angelica root, and meanwhile, the beverage has good kidney protection efficacy and is more beneficial to the recovery and prevention of gout and hyperuricemia.
In order to achieve the purpose, the applicant finally obtains a formulation of the artemisia selengensis leaf uric acid reducing beverage with enhanced efficacy by screening a large number of experiments according to the previous research results of the applicant, wherein the beverage takes artemisia selengensis leaf extracting solution as a main component, and the efficacy of the beverage is enhanced by adding a small amount of prunella vulgaris, rose, spina date seed and radix angelicae extract, and the formulation is specifically as follows:
a artemisia selengensis leaf uric acid reducing beverage with enhanced efficacy comprises an artemisia selengensis leaf extracting solution and four extracts which respectively account for the following mass percentages of the artemisia selengensis leaf extracting solution:
the four extracts are added, so that the artemisia selengensis leaves have stronger Xanthine Oxidase (XOD) inhibition activity, and the detection of the in vitro enzyme activity and the XOD activity in the liver of an animal shows that compared with the artemisia selengensis leaves beverage without the extracts, the XOD enzyme inhibition activity of the invention is obviously increased, so that the invention is more beneficial to reducing uric acid, and simultaneously, the invention can also reduce the serum creatinine (Cr) and urea nitrogen (BUN) contents of a hyperuricemia mouse, which prompts that the invention also has a certain kidney protection effect, and is more beneficial to the recovery and prevention of gout and hyperuricemia.
Research finds that the exertion of the above effects is closely related to the mixture ratio of the four extracts, which indicates that certain interaction exists among the four extracts, and when the four extracts are respectively added according to the following mixture ratios, the XOD enzyme inhibitory activity and the kidney protection effect are relatively better:
preferably, the beverage also contains the following auxiliary materials in percentage by mass in the artemisia selengensis leaf extracting solution:
7-15% of xylitol
0.05 to 0.13 percent of citric acid
0.2-1% of beta-cyclodextrin.
Further preferably, the auxiliary materials respectively account for the mass percentages of the artemisia selengensis leaf extracting solution as follows:
13 percent of xylitol
0.09 percent of citric acid
Beta-cyclodextrin 0.6%.
Further preferably, the preparation method of the chenopodium album leaf extract comprises the following steps: drying fresh artemisia selengensis leaves at 60 ℃ for 10h, then crushing, adding water according to the mass-to-volume ratio of 1:40 of material liquid, leaching at 95 ℃ for 40min, and filtering to obtain artemisia selengensis leaf extracting solution.
The invention has the beneficial effects that:
(1) the drink provided by the invention has excellent XOD (X-ray diffraction) inhibition activity in vitro, has the effect of obviously reducing blood uric acid in vivo, and has stronger effect compared with the existing chenopodium album leaves, so that the synthesis of uric acid in vivo can be better inhibited. Meanwhile, the invention can also reduce the renal function damage caused by hyperuricemia and show the protective effect on the kidney, thereby being more beneficial to the recovery and prevention of diseases.
(2) The raw materials used in the invention have natural and healthy components, low cost, good sensory quality, safety and effectiveness, and are suitable for being developed into health-care or functional foods for people with high uric acid and people with high risk of high uric acid to drink for a long time.
Detailed Description
The present invention will be further illustrated with reference to the following specific examples, but the present invention is not limited to the following examples.
As described in the background art, although the existing artemisia selengensis leaf beverage can reduce the generation of uric acid in a human body by inhibiting the activity of xanthine oxidase, the comprehensive nursing and nursing effect on the human body is poor, the beverage does not have the liver and kidney protection effect, and the recovery effect on gout and hyperuricemia is poor and not durable due to the symptoms and root causes.
Based on the above, the invention provides the artemisia selengensis leaf uric acid reducing beverage with enhanced efficacy, which is prepared by compounding an artemisia selengensis leaf extracting solution, a selfheal extract, a rose extract, a spina date seed extract and an angelica dahurica extract.
Tests show that the four extracts are compounded according to a specific proportion and added into the artemisia selengensis leaf extracting solution, so that the uric acid reducing activity can be remarkably enhanced, and the kidney is protected. The present invention has been thus made. The invention not only enriches the sources of purely natural and low-cost substances with the uric acid reducing activity, but also develops the new application value of the artemisia selengensis plant with regional characteristics and resource advantages.
In order to make the technical solutions of the present application more clearly understood by those skilled in the art, the technical solutions of the present application will be described in detail below with reference to specific embodiments. The test materials used in the examples of the present invention are all conventional in the art and commercially available.
Example 1:
100% of artemisia selengensis leaf extracting solution; 1.2 percent of selfheal extract, 1.8 percent of rose extract, 3 percent of spina date seed extract, 1.2 percent of angelica extract, 13 percent of xylitol, 0.09 percent of citric acid and 0.6 percent of beta-cyclodextrin
(1) Drying fresh folium Artemisiae Annuae at 60 deg.C for 10 hr, pulverizing, adding water at a ratio of 1:40(g folium Artemisiae Annuae dry powder: mL water), extracting at 95 deg.C for 40min, and filtering to obtain folium Artemisiae Annuae extract;
(2) blending: taking the mass of the artemisia selengensis leaf extracting solution as a reference, adding 1.2% of selfheal extract, 1.8% of rose extract, 3% of spina date seed extract, 1.2% of angelica dahurica extract, 13% of xylitol, 0.09% of citric acid and 0.6% of beta-cyclodextrin, and fully and uniformly mixing;
(3) and (3) filtering: filtering with 200 mesh filter screen to remove part of insoluble impurities;
(4) filling: filling;
(5) and (3) sterilization: sterilizing with high temperature sterilizing equipment.
The following examples were prepared in the same manner as in example 1.
Example 2:
100% of artemisia selengensis leaf extracting solution; 0.2 percent of selfheal extract, 0.6 percent of rose extract, 0.6 percent of spina date seed extract, 0.2 percent of angelica dahurica extract, 9 percent of xylitol, 0.07 percent of citric acid and 1 percent of beta-cyclodextrin
Example 3:
100% of artemisia selengensis leaf extracting solution; 0.2 percent of selfheal extract, 1.8 percent of rose extract, 1.8 percent of spina date seed extract, 1.2 percent of angelica dahurica extract, 11 percent of xylitol, 0.05 percent of citric acid and 0.8 percent of beta-cyclodextrin
Example 4:
100% of artemisia selengensis leaf extracting solution; 0.2 percent of selfheal extract, 3 percent of rose extract, 3 percent of spina date seed extract, 2.2 percent of angelica extract, 7 percent of xylitol, 0.11 percent of citric acid and 0.4 percent of beta-cyclodextrin
Example 5:
100% of artemisia selengensis leaf extracting solution; 1.2 percent of selfheal extract, 0.6 percent of rose extract, 1.8 percent of spina date seed extract, 2.2 percent of angelica dahurica extract, 13 percent of xylitol, 0.13 percent of citric acid and 1 percent of beta-cyclodextrin
Example 6:
100% of artemisia selengensis leaf extracting solution; 1.2 percent of selfheal extract, 1.8 percent of rose extract, 3 percent of spina date seed extract, 0.2 percent of angelica extract, 15 percent of xylitol, 0.05 percent of citric acid and 0.2 percent of beta-cyclodextrin
Example 7:
100% of artemisia selengensis leaf extracting solution; 1.2 percent of selfheal extract, 3 percent of rose extract, 0.6 percent of spina date seed extract, 1.2 percent of angelica extract, 11 percent of xylitol, 0.07 percent of citric acid and 0.6 percent of beta-cyclodextrin
Example 8:
100% of artemisia selengensis leaf extracting solution; 2.2 percent of selfheal extract, 0.6 percent of rose extract, 3 percent of spina date seed extract, 1.2 percent of angelica extract, 7 percent of xylitol, 0.05 percent of citric acid and 0.8 percent of beta-cyclodextrin
Example 9:
100% of artemisia selengensis leaf extracting solution; 2.2 percent of selfheal extract, 1.8 percent of rose extract, 0.6 percent of spina date seed extract, 2.2 percent of angelica dahurica extract, 9 percent of xylitol, 0.09 percent of citric acid and 0.4 percent of beta-cyclodextrin
Example 10:
100% of artemisia selengensis leaf extracting solution; 2.2 percent of selfheal extract, 3 percent of rose extract, 1.8 percent of spina date seed extract, 0.2 percent of angelica dahurica extract, 15 percent of xylitol, 0.05 percent of citric acid and 0.6 percent of beta-cyclodextrin
Comparative example:
100 percent of artemisia selengensis leaf extracting solution.
Test example 1 Effect of extract on in vitro uric acid lowering Effect of Artemisia selengensis leaf
The in vitro XOD inhibition rate determination method comprises the following steps: the enzyme reaction was carried out using a 96-well plate, and 20. mu.L of the sample solution to be assayed and 100. mu.L of the xanthine oxidase solution (9.375X 10) were sequentially added-7mol/L) is added into an enzyme labeling hole; incubating enzyme reaction compound at 37 deg.C for 2min, adding 40 μ L xanthine substrate solution (1mmol/L) to start reaction, measuring light absorption value of reaction system every 10s for 1 time, and detecting change K of light absorption value of reaction system at 295nm within 2min1The change of absorbance of Phosphate Buffered Saline (PBS) control group was K0Calculating the enzyme activity inhibition rate according to a formula:
inhibition ratio (%) - (1-K)1/K0)×100％
TABLE 1 in vitro XOD inhibition
| XOD in vitro inhibition (%) | |
| Example 1 | 84.59±0.60** |
| Example 2 | 76.08±2.63 |
| Example 3 | 81.70±4.23* |
| Example 4 | 81.68±0.91* |
| Example 5 | 81.04±0.96* |
| Example 6 | 83.83±0.97** |
| Example 7 | 80.53±1.43 |
| Example 8 | 82.70±1.73** |
| Example 9 | 77.75±4.73 |
| Example 10 | 79.45±4.18 |
| Comparative example | 74.21±0.10 |
Note: each group was compared with the comparative example,*indicating a significant difference (p)<0.05)，**Indicates a very significant difference (p)<0.01)。
Test example 2 Effect on hyperuricemia mice
1. Test sample
Concentrating the stock solution, wherein the gavage concentration is 3 times of that of the stock solution, and the gavage amount of each mouse is 0.2mL/10g according to the daily body weight.
2. Animal grouping and administration method
70 healthy male Kunming mice are selected, the SPF level is achieved, the age is 4 weeks, and the mice are provided by the animal center of Huazhong agricultural university; the mice are adaptively raised for one week under the experimental environment, and are randomly divided into a blank control group, a model control group, a positive control group, examples 1-10 and a comparative example group from the 7 th day, wherein the weight distribution of the mice in each group is similar.
And (3) molding: the blank control group was subjected to intragastric administration with 0.5% CMC-Na in an amount of 0.1mL/10g based on the body weight of the blank control group, and the remaining groups were subjected to intragastric administration with potassium oxonate in an amount of 0.1mL/10g based on the body weight of the remaining groups, and molding was performed.
The administration period is as follows: after molding for 1h, the blank control group and the model control group were subjected to intragastric administration of 0.5% CMC-Na in an amount of 0.1mL/10g based on the body weight thereof, the positive control group was subjected to intragastric administration of 5mg/kg allopurinol in an amount of 0.1mL/10g based on the body weight thereof, and the test group was subjected to intragastric administration of 0.2mL/10g beverage in an amount of 0.2mL/10g based on the body weight thereof. Repeat for 7 days once a day.
The mice had an empty stomach for 12h before death (fasting without water), and after 1h of last administration, the mice were subjected to eyeball picking and blood sampling, and serum was separated; kidneys and liver were removed after dissection. Uric Acid (UA), urea nitrogen (BUN), Creatinine (CRE) levels, and Xanthine Oxidase (XOD) activity in the liver were determined in each group of mice serum.
3. Results and analysis of the experiments
TABLE 2 serum Uric Acid (UA) content and liver XOD viability assay
| Group of | UA(μmol/L) | XOD(U/g) |
| Blank control group | 226.3±34.2 | 45.3±4.0 |
| Model control group | 270.7±40.6** | 48.4±7.8* |
| Positive control group | 131.4±29.7## | 42.1±3.1## |
| EXAMPLE 1 group | 227.9±64.6## | 44.3±1.2## |
| Comparative example group | 253.4±39.3# | 46.5±5.1 |
Note: compared with the blank control group, the composition of the composition,*indicating a significant difference (p)<0.05),**Indicates a very significant difference (p)<0.01); compared with the model control group,#indicating a significant difference (p)<0.05),##Indicates a very significant difference (p)<0.01)。
The results of the serum uric acid content and liver XOD activity measurement are shown in Table 2, and the results show that: the example and the comparative group can reduce the serum uric acid content of the mice and the XOD activity of the liver, and the effect of the example 1 is obviously better than that of the comparative group.
TABLE 3 serum creatinine (Cr) and urea nitrogen (BUN) assay
Note: compared with the blank control group, the composition of the composition,*indicating a significant difference (p)<0.05),**Indicates a very significant difference (p)<0.01); compared with the model control group,#indicating a significant difference (p)<0.05),##Indicates a very significant difference (p)<0.01)。
The effect on serum creatinine (Cr) and urea nitrogen (BUN) content in uric acid-rich mice is shown in table 3. Creatinine and urea nitrogen in serum are metabolized through the kidney, the two index results are generally used for representing the influence and damage of substances on the mouse kidney function clinically, and the increase of serum creatinine and urea nitrogen indicates the damage of the kidney function. Compared with the model control group, the serum creatinine value and the serum urea nitrogen value of the mice in the group of the example 1 are obviously reduced, which indicates that the mice have the effect of protecting the kidney. And the effect of example 1 is more remarkable than that of the other examples.
Mouse experiments show that the four extracts used in the invention can enhance the activity of the chenopodium album leaves in the aspects of reducing uric acid and protecting kidney, and the effect is closely related to the proportion of the four extracts, which indicates that certain interaction exists among the four extracts.
Test example 3 sensory evaluation test
Functional drinks should provide consumers with good sensory enjoyment in addition to providing nutritional ingredients and specific functions. Therefore, the present invention also carried out sensory evaluation of the prepared beverage.
The sensory score was determined as follows: the three sensory evaluation aspects of mouthfeel, aroma and appearance were tasted and scored by 8 food workers.
TABLE 4 sensory Scoring criteria
TABLE 5 sensory Scoring results
| Sensory scoring | |
| Example 1 | 86 |
| Example 2 | 85 |
| Example 3 | 83 |
| Example 4 | 79 |
| Example 5 | 88 |
| Example 6 | 88 |
| Example 7 | 84 |
| Example 8 | 72 |
| Example 9 | 75 |
| Example 10 | 80 |
| Comparative example | 63 |
The results show that the beverage prepared by the invention has higher sensory score.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (5)
1. The efficacy-enhanced artemisia selengensis leaf uric acid-reducing beverage is characterized in that: the beverage contains artemisia selengensis leaf extracting solution and four extracts which respectively account for the following mass percentages of the artemisia selengensis leaf extracting solution:
2. the artemisia selengensis leaf uric acid reducing beverage of claim 1, wherein: the four extracts respectively account for the weight percentages of the artemisia selengensis leaf extracting solution as follows:
3. the artemisia selengensis leaf uric acid reducing beverage of claim 1, wherein: the beverage also contains the following auxiliary materials in percentage by mass in the artemisia selengensis leaf extracting solution:
7-15% of xylitol
0.05 to 0.13 percent of citric acid
0.2-1% of beta-cyclodextrin.
4. The artemisia selengensis leaf uric acid reducing beverage of claim 3, wherein: the auxiliary materials respectively account for the artemisia selengensis leaf extracting solution in percentage by mass:
13 percent of xylitol
0.09 percent of citric acid
Beta-cyclodextrin 0.6%.
5. The artemisia selengensis leaf uric acid reducing beverage of claim 3, wherein the artemisia selengensis leaf extracting solution is prepared by the following steps: drying fresh artemisia selengensis leaves at 60 ℃ for 10h, then crushing, adding water according to the mass-to-volume ratio of 1:40 of material liquid, leaching at 95 ℃ for 40min, and filtering to obtain artemisia selengensis leaf extracting solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210210953.5A CN114532468A (en) | 2022-03-03 | 2022-03-03 | Efficacy-enhanced artemisia selengensis leaf uric acid-reducing beverage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210210953.5A CN114532468A (en) | 2022-03-03 | 2022-03-03 | Efficacy-enhanced artemisia selengensis leaf uric acid-reducing beverage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114532468A true CN114532468A (en) | 2022-05-27 |
Family
ID=81661149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210210953.5A Pending CN114532468A (en) | 2022-03-03 | 2022-03-03 | Efficacy-enhanced artemisia selengensis leaf uric acid-reducing beverage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114532468A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997843A (en) * | 2015-08-07 | 2015-10-28 | 国药集团健康产业研究院有限公司 | Application of selfheal extract for making blood uric acid decreasing medicine or food |
| CN107223830A (en) * | 2017-04-20 | 2017-10-03 | 南昌大学 | A kind of method for preparing the gentle solution gout drinks of prevention |
| CN108434363A (en) * | 2018-05-22 | 2018-08-24 | 李晶 | A kind of Chinese medicine composition and preparation method thereof for anti-trioxypurine |
| CN108619270A (en) * | 2018-05-29 | 2018-10-09 | 华中农业大学 | A kind of composition with xanthine oxidase inhibitory activity |
| CN110237064A (en) * | 2019-06-10 | 2019-09-17 | 华中农业大学 | Purposes of double caffeoylquinic acids in preparation treatment gout drug |
| CN110916033A (en) * | 2019-11-07 | 2020-03-27 | 南方医科大学 | Beverage for reducing uric acid and preparation method thereof |
| CN111419894A (en) * | 2020-05-29 | 2020-07-17 | 鲁雪梅 | Pharmaceutical composition for reducing uric acid and preparation method thereof |
| CN111760014A (en) * | 2020-07-20 | 2020-10-13 | 厦门植喜生物科技有限公司 | A composition for reducing acid and invigorating kidney, and its preparation method |
| CN113951410A (en) * | 2021-10-20 | 2022-01-21 | 植仁(武汉)健康产业有限公司 | Anti-gout beverage and preparation method thereof |
-
2022
- 2022-03-03 CN CN202210210953.5A patent/CN114532468A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997843A (en) * | 2015-08-07 | 2015-10-28 | 国药集团健康产业研究院有限公司 | Application of selfheal extract for making blood uric acid decreasing medicine or food |
| CN107223830A (en) * | 2017-04-20 | 2017-10-03 | 南昌大学 | A kind of method for preparing the gentle solution gout drinks of prevention |
| CN108434363A (en) * | 2018-05-22 | 2018-08-24 | 李晶 | A kind of Chinese medicine composition and preparation method thereof for anti-trioxypurine |
| CN108619270A (en) * | 2018-05-29 | 2018-10-09 | 华中农业大学 | A kind of composition with xanthine oxidase inhibitory activity |
| CN110237064A (en) * | 2019-06-10 | 2019-09-17 | 华中农业大学 | Purposes of double caffeoylquinic acids in preparation treatment gout drug |
| CN110916033A (en) * | 2019-11-07 | 2020-03-27 | 南方医科大学 | Beverage for reducing uric acid and preparation method thereof |
| CN111419894A (en) * | 2020-05-29 | 2020-07-17 | 鲁雪梅 | Pharmaceutical composition for reducing uric acid and preparation method thereof |
| CN111760014A (en) * | 2020-07-20 | 2020-10-13 | 厦门植喜生物科技有限公司 | A composition for reducing acid and invigorating kidney, and its preparation method |
| CN113951410A (en) * | 2021-10-20 | 2022-01-21 | 植仁(武汉)健康产业有限公司 | Anti-gout beverage and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王晓梅: "三种中药提取物对黄嘌呤氧化酶的抑制作用", 氨基酸和生物资源, pages 57 - 60 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017101878A4 (en) | Gynostemma pentaphyllum containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia, and gout | |
| CN102552493A (en) | Anti-inebriation drunk-preventing composition and preparation method thereof | |
| KR20200120465A (en) | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution | |
| CN108201138A (en) | A kind of preparation and preparation method thereof of relieving alcoholism and protecting liver composition, composition | |
| KR101789424B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine Proving Insomniac and the Method of Making the Same | |
| KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
| CN105558198A (en) | Health-care tea capable of reducing blood sugar and preparation method of health-care tea | |
| KR101890796B1 (en) | COMPOSITION FOR PREVENTING OR ALLEVIATING HANGOVER COMPRISING EXTRACTS OF GINGSENG BERRY, EXTRACTS OF Hovenia dulcis Thunberg AND MINERRAL CONCENTRATE | |
| CN103637190A (en) | Functional food for prevention and treatment of diabetes and its preparation method | |
| CN103349675A (en) | Medical use of vegetable soybeans in diabetes prevention and treatment | |
| CN102596214B (en) | Composition for alleviating fatty liver | |
| US20140057002A1 (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
| CN114532468A (en) | Efficacy-enhanced artemisia selengensis leaf uric acid-reducing beverage | |
| CN114947129A (en) | Uric acid-reducing cichorium grandiflorum and angelica dahurica health food and preparation method thereof | |
| CN101411781A (en) | Use of pu'er tea in preparing medicament for treating or preventing diabetes | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN104664011B (en) | A kind of composition with clearing healthcare function and preparation method thereof | |
| CN106727902A (en) | Relieving alcoholism and protecting liver Chinese medicine composition and its application containing Cordyceps sinensis | |
| CN108379455B (en) | Uric acid reducing composition | |
| KR100642801B1 (en) | Anti-diabetic food composition comprising extracts from natural herbal materials and pear and process for preparing the same | |
| CN105597083B (en) | A kind of pair of liver kidney has health food of auxiliary protection function and preparation method thereof | |
| Airaodion et al. | Chemical Composition and Nutraceutical Potential of Velvet Tamarind (Dialium guineense wild) Fruit Pulp | |
| KR20110101916A (en) | Composition for antifati gue containin g herbal mixture extract as in gredient compounds | |
| KR20190116003A (en) | Composition for hangover treatment and manufacturing method for the same | |
| CN105875961A (en) | Lung moistening and phlegm eliminating healthy tea beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |